Canada markets close in 23 minutes

Atossa Therapeutics, Inc. (ATOS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.7728-0.0572 (-3.13%)
As of 03:34PM EDT. Market open.

Atossa Therapeutics, Inc.

107 Spring Street
Seattle, WA 98104
United States
206 588 0256
https://atossatherapeutics.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees11

Key Executives

NameTitlePayExercisedYear Born
Dr. Steven C. Quay FCAP, M.D., Ph.D.Chairman, CEO & President1.14MN/A1951
Ms. Heather ReesSVP, Finance & Principal Accounting OfficerN/AN/A1972
Ms. Delly Behen P.H.R.Senior Vice President of Administration & HRN/AN/AN/A
Mr. Eric Van ZantenVice President of Investor & Public RelationsN/AN/AN/A
Dr. Richard Graydon M.D., Ph.D.Interim Chief Medical OfficerN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Corporate Governance

Atossa Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.